Home / Markets / Industries / Health Care

Tuesday, May 05, 2009

Medicis Announces First Quarter 2009 Conference Call and Webcast

Comtex

SCOTTSDALE, Ariz., May 5, 2009 (GlobeNewswire via COMTEX) ----Medicis (NYSE:MRX) today announced it expects to report 2009 first quarter financial results after the market closes on Thursday, May 7, 2009. Medicis will host a conference call at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) to review the March 31, 2009, first quarter financial results, as well as provide an update on other business matters of the Company. A live webcast will be available at http://www.Medicis.com/company/index.asp. The webcast will be archived on the Company's website for 10 business days following the live call.

Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (877) 567-5763 (U.S. and Canada) or +1 (706) 679-4760 (international and local). The access code for the live call is 94831465. For investors unable to participate in the live call, a replay will be available soon after the live call. The phone number to access the replay is +1 (800) 642-1687 (U.S. and Canada) or +1 (706) 645-9291 (international and local). The access code for the replay is 94831465. The replay will be available for 10 business days following the live call.

About Medicis

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic and aesthetic categories. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and aesthetic elegance.

The Company's products include the brands RESTYLANE(R) (hyaluronic acid), PERLANE(R) (hyaluronic acid), DYNACIN(R) (minocycline HCl), DYSPORT(TM) (abobotulinumtoxinA), LOPROX(R) (ciclopirox), PLEXION(R) (sodium sulfacetamide 10% and sulfur 5%), SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets, TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream 0.05%, VANOS(R) (fluocinonide) Cream 0.1%, ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10%, the LIPOSONIX(R)(1) system and the over-the-counter brand ESOTERICA(R).

For more information about Medicis, please visit the Company's website at www.Medicis.com. Printed copies of the Company's complete audited financial statements are available free of charge upon request.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Medicis expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by Medicis based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. No assurances can be given, however, that these activities, events or developments will occur or that such results will be achieved. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Medicis. Several of these risks are outlined in the Company's most recent annual report on Form 10-K for the year ended December 31, 2008, and other documents we file with the Securities and Exchange Commission. Forward-looking statements represent the judgment of Medicis' management as of the date of this release, and Medicis disclaims any intent or obligation to update any forward-looking statements contained herein, which speak as of the date hereof.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company. RESTYLANE(R) and PERLANE(R) are trademarks of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical Corporation. All other trademarks are the property of their respective owners.

(1) The LIPOSONIX(R) system is currently not approved for sale or use in the U.S.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Medicis Pharmaceutical Corporation

Medicis
   Kara Stancell
   (480) 291-5854

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
   
   **********************************************************************
   
   As of Friday, 05-01-2009 23:59, the latest Comtex SmarTrend� Alert, 
   an automated pattern recognition system, indicated an UPTREND on 
   12-03-2008 for MRX @ $12.93.
   
   For more information on SmarTrend, contact your market data
   provider or go to www.mysmartrend.com
   
   SmarTrend is a registered trademark of Comtex News Network, Inc.
   Copyright � 2004-2009 Comtex News Network, Inc. All rights reserved.

FOX Translator

Indices

No data currently available.

Top Stock Gainers

No data currently available.

Most Searched Symbols

SYMBOL

Word of the Day

Marriage Penalty

Sure, we know some of you are saying the term "marriage penalty" is redundant. In fact, of all the costs associated with getting married (have you seen the cost of a wedding cake lately?), the marriage penalty can be the worst.

Here's how it works: Mr. and Mrs. Right walk down the aisle in wedded bliss and suddenly they¿re a two-income household. If both make roughly the same amount of money, they can be pushed into a higher tax bracket. That's bad, since the higher the bracket, the higher the tax. So, if both were single, they'd end up writing two smaller checks to the tax man that, if combined, would add up to less than the giant check they write in a state of wedded bliss.

Is that fair? We're not touching that, but there is a flip side that few people talk about. The marriage penalty only kicks in if both members of the couple make close to the same amount of money. If there's a big disparity in pay, there's actually a tax advantage. Call it the marriage bonus.

And, it¿s important to remember that there are other financial benefits, such as lower life-insurance rates or health care premiums, that can make up for the extra tax couples pay. So don't let Uncle Sam stop you from saying, "I do."